-+ 0.00%
-+ 0.00%
-+ 0.00%
Peptron Wins South Korean Approval for PT403 Phase 1 Obesity Trial
Share
Listen to the news
Peptron Wins South Korean Approval for PT403 Phase 1 Obesity Trial
  • Peptron received South Korean regulatory clearance on Nov. 18, 2026, for a Phase 1 trial of obesity candidate PT403.
  • The trial will assess safety, tolerability and pharmacokinetics in 22 healthy adults, with completion expected Nov. 30, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Peptron Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261119900001), on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending